| Bioactivity | SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS-CoV-2 3CLpro-IN-19 has broad-spectrum activity against Omicron subvariants (BA.5, BQ.1.1, and XBB.1.5) infection in human cells, with EC50 values between 30-69 nM[1]. |
| Target | 0.7 μM (SARS-CoV-2 3CLpro) |
| Name | SARS-CoV-2 3CLpro-IN-19 |
| Formula | C24H22ClN3O2S |
| Molar Mass | 451.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Pérez-Vargas J, et al. A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants. Emerg Microbes Infect. 2023 Dec;12(2):2246594. |
SARS-CoV-2 3CLpro-IN-19
CAS: F: C24H22ClN3O2S W: 451.97
SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide SARS-CoV-2 3CLpro inhibitor (IC50s: 0.7 μM). SARS
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.